计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B414037-5mg |
5mg |
期货 ![]() |
| |
| B414037-25mg |
25mg |
期货 ![]() |
| |
| B414037-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | 1357920-84-3 | AKOS037648708 | BCP29521 | Belizatinib [WHO-DD] | D80502 | EX-A1509 | SCHEMBL22567114 | SCHEMBL573248 | BDBM50396243 | BDBM513991 | s8511 | SCHEMBL19328244 | Belizatinib(TSR-011) | SCHEMBL573249 | GTPL10474 | Belizatinib (TSR011) | Belizati |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Belizatinib (TSR-011) |
| 生化机理 | "贝利扎替尼(TSR-011)是ALK(IC50=0.7 nM)和肌球蛋白受体激酶(TRK)的强效抑制剂(TRK A、B和C的IC50值小于3 nM)"。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | ALK 受体酪氨酸激酶抑制剂;AXL 受体酪氨酸激酶抑制剂;fms 相关受体酪氨酸激酶 3 抑制剂;白细胞介素 1 受体相关激酶 1 抑制剂;白细胞受体酪氨酸激酶抑制剂 MER 原癌基因酪氨酸激酶抑制剂丝裂原活化蛋白激酶激酶 2 |
| 产品介绍 |
Information "Belizatinib (TSR-011) is a potent inhibitor ofALK(IC50=0.7 nM) andtropomyosin receptor kinase (TRK)(IC50 values less than 3 nM for TRK A, B, and C). " Targets TrkA ; TrkB ; TrkC ; TrkA ; TrkB 28040,; In vitro TSR-011 has high affinity for wild-type recombinant ALK kinase activity, with an IC50 value of 0.7\u2009nM and inhibits tropomyosin receptor kinase (TRK) A, B, and C (IC50 < 3nM). In vivo TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models. It is well-tolerated. |
| ALogP | 4.827 |
|---|---|
| HBD Count | 2 |
| Rotatable Bond | 7 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771562 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | 4-fluoro-N-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide |
| INCHI | InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41) |
| InChi Key | WSTUJEXAPHIEIM-UHFFFAOYSA-N |
| Canonical SMILES | CC(C)NC(=O)C1CCC(CC1)N2C3=C(C=CC(=C3)CN4CCC(CC4)C(C)(C)O)N=C2NC(=O)C5=CC=C(C=C5)F |
| Isomeric SMILES | CC(C)NC(=O)C1CCC(CC1)N2C3=C(C=CC(=C3)CN4CCC(CC4)C(C)(C)O)N=C2NC(=O)C5=CC=C(C=C5)F |
| PubChem CID | 57345941 |
| 分子量 | 577.73 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (173.09 mM); Ethanol: 100 mg/mL (173.09 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 100 |
| DMSO(mM) Max Solubility | 173.0912364 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 577.700 g/mol |
| XLogP3 | 4.500 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 8 |
| 精确质量Exact Mass | 577.343 Da |
| 单同位素质量Monoisotopic Mass | 577.343 Da |
| 拓扑极表面积Topological Polar Surface Area | 99.500 Ų |
| 重原子数Heavy Atom Count | 42 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 909.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC) | 98-100(%) |
|---|---|
| Proton NMR spectrum | Conforms to structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 25-04-03 | B414037 |
| 1. Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H et al.. (2012) The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.. J Med Chem, 55 (14): (6523-40). [PMID:22734674] |